Galápagos and GSK expand their discovery alliance in arthritis

Wednesday 16 December 2009

Galápagos NV said that it has expanded its collaboration with GlaxoSmithKline to discover new drugs for multiple indications in the field of arthritis. The two companies are exploring drugs directed at the kinase target GT622.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium